Biohacking
AI tool and fruit fly experiments link BRSK1 gene variants to rare brain disorder
By Life and Health Today Staff, . Life and Health Today.
For years, families enrolled in the Texome Project, a Texas initiative that provides free comprehensive genomic testing to medically underserved families, had genomic data but no answer. Standard parent-child trio sequencing, which reads the genetic code of a child and both parents to look for inherited or new mutations, kept coming up empty for one child with unexplained neurological symptoms.
The break came from an artificial intelligence tool called AI-MARRVEL, which cross-references genomic data with clinical presentation and databases from multiple biological systems to rank which mutations are most likely to be causing disease. According to Genetic Engineering News and Neuroscience News, both of which covered the study, AI-MARRVEL flagged a rare change in a gene called BRSK1 as the most plausible culprit.
BRSK1 encodes a kinase, a protein that switches other proteins on or off by adding a phosphate group to them. This particular kinase is involved in neuronal polarization, the process by which a developing nerve cell establishes which end will send signals and which will receive them, as well as in synapse formation and the internal scaffolding of neurons.
Once the candidate gene was identified, the research team posted it to GeneMatcher, a global database that connects geneticists working on the same gene. That search turned up nine additional affected individuals, bringing the total to 10 people from seven unrelated families, according to the study as reported by both outlets.
Every one of those individuals showed some degree of global developmental delay. Beyond that, the picture was variable: anxiety, attention-deficit hyperactivity disorder, autism traits, and seizures appeared in some but not all. Neuroscience News noted that even family members carrying the identical mutation sometimes had very different symptom severity, ranging from mild learning difficulties to more significant neurological impairment. That kind of within-family variation, called variable expressivity, is one of the harder features of rare genetic disorders to explain and remains an open question here.
To move from association to mechanism, the team turned to Drosophila melanogaster, the common fruit fly. The fly carries its own version of BRSK1, a gene called sff, short for sugar-free frosting. According to Genetic Engineering News, first author Mingxi Deng, a postdoctoral fellow in the lab of co-lead author Hugo Bellen at Baylor College of Medicine, reported that sff is active primarily in neurons, mirroring the human gene's expression pattern.
When the researchers disabled sff entirely, the flies developed movement difficulties, became more sensitive to stressors that trigger seizure-like behavior, grew more vulnerable to heat-induced paralysis, and lived shorter lives. Introducing normal human BRSK1 into those flies largely corrected those deficits, which, as Genetic Engineering News reported, confirmed that the human and fly versions of the gene serve the same biological function across hundreds of millions of years of evolution.
The critical test was what happened when the researchers introduced the specific variants found in the human patients rather than the healthy version of the gene. Three variants, identified in the Genetic Engineering News report as BRSK1p.Ile202Val, BRSK1p.Arg237Cys, and BRSK1p.Thr406Ile, only partially corrected the flies' problems. The variants also failed to normalize the structure of neuromuscular junctions, the connection points between nerves and muscles, or levels of a protein called Futsch, which helps organize the internal microtubule skeleton of neurons. Microtubules are the structural tracks inside cells along which cargo is transported; disruption of that system has been linked to several neurodevelopmental conditions, according to Deng as quoted by Genetic Engineering News.
The overall picture, as both outlets described it, is that these patient variants are partial loss-of-function mutations, meaning they reduce BRSK1 activity without eliminating it entirely. That partial reduction appears to be enough to interfere with normal brain development.
What this work does not establish is a treatment. The study identifies a cause and a mechanism in fruit flies; it does not test any intervention in humans or animals. It also does not yet explain why the same mutation can produce such different outcomes in different people, which the authors acknowledged as a question for future research, according to Genetic Engineering News.
For the families involved, the immediate value is diagnostic: a name for what has been happening. For the broader field, the study is a demonstration that combining AI-driven variant prioritization with model organism experiments can resolve cases that standard sequencing cannot. Whether that pipeline will scale to the many thousands of families still waiting for answers is the question worth watching.
If you are navigating an undiagnosed condition, the findings here are not actionable without a clinician who knows your specific history and can assess whether genetic testing through a program like the Texome Project is appropriate for your situation.
Source: https://neurosciencenews.com/neurodevelopmental-brsk1-genetics-31269/